Seres’ SER-287 for UC Shows Positive Results in Phase 1b Trial

Seres’ SER-287 for UC Shows Positive Results in Phase 1b Trial
Seres Therapeutics announced positive topline results from the company’s Phase 1b placebo-controlled study investigating the effects of SER-287, a potential microbiome therapy, in patients with ulcerative colitis (UC) who failed to respond to current therapies. The study is ongoing and actively recruiting participants. The results revealed that patients treated with SER-287 showed a dose-dependent benefit in clinical remission rates, and an improvement of mucosal appearance by endoscopy. Importantly, the therapy did not raise safety concerns. "We are extremely pleased with these SER-287 Phase 1b efficacy and safety study results. The clinical data demonstrate the potential for microbiome therapeutics to provide an effective and safer alternative treatment modality for patients suffering from ulcerative colitis,” Roger J. Pomerantz, MD, president and CEO of Seres, said in a press release. "Based on the strength of these data, Seres intends to work expeditiously to advance SER-287 into more advanced development studies," he said. "We plan to further evaluate SER-287 in mild, moderate and severe forms of ulcerative colitis, in maintenance after induction therapy, and we also intend to assess development in Crohn’s disease, and pediatric forms of inflammatory bowel disease." Pomerantz said he expects to discuss the data with the U.S. Food and Drug Administration (FDA) "as soon as possible to determine the most accelerated path to advance SER-287 development
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *